Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“Dynamic biomarkers with FTD/TPI ± BEV in mCRC
- n=112 (matched analysis)
- OS: 10.5 vs 6.2 mo (HR 0.53) with +BEV ↑IL-8 /
- ↑IFI16 → worse prognosis
- ↓AREG → better survival
- ↓EREG → benefit with FTD/TPI+BEV
On-treatment biomarkers may guide personalization.”
Other articles featuring Nieves Martinez Lago on OncoDaily.